Rheumatology and immunology, Tianjin First Central Hospital, Tianjin, China.
Skin Res Technol. 2024 May;30(5):e13701. doi: 10.1111/srt.13701.
Dermatomyositis (DM) is a rare inflammatory disease. Our research focuses on predicting poor prognosis in DM patients and evaluating the prognostic significance of ferritin and Salivary Sugar Chain Antigen-6 (KL-6) through multivariate logistic regression analysis.
Between February 2018 and April 2020, 80 DM patients at our hospital were categorized into MDA5 positive (n = 20) and negative (n = 60) groups. We conducted multivariate logistic regression to determine DM's poor prognosis risk factors and evaluate ferritin/KL-6's predictive value for prognosis.
Analysis showed no gender, age, body mass index (BMI), or lifestyle (smoking, drinking) differences, nor in dyspnea, muscle weakness, skin ulcers, and acetylcysteine treatment effects (p > 0.05). Significant differences emerged in arrhythmias, interstitial pneumonia, C-reactive protein, albumin, and lactate dehydrogenase levels (p < 0.05). Before treatment, differences were negligible (p > 0.05), but post-treatment, serum KL-6 and ferritin levels dropped. MDA5 positive patients had elevated serum KL-6 and ferritin levels than survivors (p < 0.05), with a strong correlation to DM. Combined diagnosis using serum KL-6 and ferritin for DM prognosis showed area under curves of 0.716 and 0.634, significantly outperforming single-index diagnoses with an area under curve (AUC) of 0.926 (p < 0.05).
Serum KL-6 and ferritin show marked abnormalities in DM, useful as indicators for evaluating polymyositis and DM conditions. However, the study's small sample size is a drawback. Expanding the sample size is essential to monitor serum KL-6 and ferritin changes in DM patients under treatment more closely, aiming to improve clinical assessment and facilitate detailed research.
皮肌炎(DM)是一种罕见的炎症性疾病。我们的研究重点是通过多变量逻辑回归分析预测 DM 患者的不良预后,并评估铁蛋白和唾液糖链抗原-6(KL-6)的预后意义。
在 2018 年 2 月至 2020 年 4 月期间,我院将 80 例 DM 患者分为 MDA5 阳性(n=20)和阴性(n=60)组。我们进行了多变量逻辑回归分析,以确定 DM 的不良预后风险因素,并评估铁蛋白/KL-6 对预后的预测价值。
分析显示,在性别、年龄、体重指数(BMI)或生活方式(吸烟、饮酒)方面无差异,呼吸困难、肌肉无力、皮肤溃疡和乙酰半胱氨酸治疗效果也无差异(p>0.05)。心律失常、间质性肺炎、C 反应蛋白、白蛋白和乳酸脱氢酶水平存在显著差异(p<0.05)。治疗前差异较小(p>0.05),但治疗后血清 KL-6 和铁蛋白水平下降。MDA5 阳性患者的血清 KL-6 和铁蛋白水平高于幸存者(p<0.05),与 DM 有很强的相关性。联合诊断血清 KL-6 和铁蛋白对 DM 预后的曲线下面积为 0.716 和 0.634,明显优于单一指标诊断的曲线下面积(AUC)为 0.926(p<0.05)。
DM 患者血清 KL-6 和铁蛋白明显异常,可作为评估多发性肌炎和 DM 病情的指标。然而,本研究的样本量较小是一个缺点。扩大样本量对于更密切地监测治疗中 DM 患者的血清 KL-6 和铁蛋白变化至关重要,旨在改善临床评估并促进详细研究。